9i56
From Proteopedia
(Difference between revisions)
(New page: '''Unreleased structure''' The entry 9i56 is ON HOLD Authors: Walter, A., Atz, K., Stenzhorn, Y., Nippa, D., Grether, U., Kuhn, B., Martin, R., Benz, J. Description: CRYSTAL STRUCTURE ...) |
|||
| (2 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==CRYSTAL STRUCTURE OF HUMAN MONOACYLGLYCEROL LIPASE WITH COMPOUND 23== | |
| + | <StructureSection load='9i56' size='340' side='right'caption='[[9i56]], [[Resolution|resolution]] 1.49Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[9i56]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=9I56 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=9I56 FirstGlance]. <br> | ||
| + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.49Å</td></tr> | ||
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=A1IZY:[4-(5-chloranyl-[1,3]oxazolo[4,5-b]pyridin-2-yl)piperazin-1-yl]-[2-(4-cyclopentylpyridin-3-yl)-1,3-benzoxazol-6-yl]methanone'>A1IZY</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=9i56 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=9i56 OCA], [https://pdbe.org/9i56 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=9i56 RCSB], [https://www.ebi.ac.uk/pdbsum/9i56 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=9i56 ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | == Function == | ||
| + | [https://www.uniprot.org/uniprot/MGLL_HUMAN MGLL_HUMAN] Converts monoacylglycerides to free fatty acids and glycerol. Hydrolyzes the endocannabinoid 2-arachidonoylglycerol, and thereby contributes to the regulation of endocannabinoid signaling, nociperception and perception of pain (By similarity). Regulates the levels of fatty acids that serve as signaling molecules and promote cancer cell migration, invasion and tumor growth.<ref>PMID:20079333</ref> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | The rapid and economical synthesis of novel bioactive compounds remains a hurdle in drug discovery efforts. This study demonstrates an integrated medicinal chemistry workflow that effectively diversifies hit and lead structures, enabling an acceleration of the critical hit-to-lead optimization phase. Employing high-throughput experimentation (HTE), we generated a comprehensive data set encompassing 13,490 novel Minisci-type C-H alkylation reactions. These data served as the foundation for training deep graph neural networks to accurately predict reaction outcomes. Scaffold-based enumeration of potential Minisci reaction products, starting from moderate inhibitors of monoacylglycerol lipase (MAGL), yielded a virtual library containing 26,375 molecules. This virtual chemical library was evaluated using reaction prediction, physicochemical property assessment, and structure-based scoring, identifying 212 MAGL inhibitor candidates. Of these, 14 compounds were synthesized and exhibited subnanomolar activity, representing a potency improvement of up to 4500 times over the original hit compound. These ligands also showed favorable pharmacological profiles. Co-crystallization of three computationally designed ligands with the MAGL protein provided structural insights into their binding modes. This study demonstrates the potential of combining miniaturized HTE with deep learning and optimization of molecular properties to reduce cycle times in hit-to-lead progression. | ||
| - | + | Expediting hit-to-lead progression in drug discovery through reaction prediction and multi-dimensional optimization.,Nippa DF, Atz K, Stenzhorn Y, Muller AT, Tosstorff A, Benz J, Binch H, Burkler M, Haider A, Heer D, Hochstrasser R, Kramer C, Reutlinger M, Schneider P, Shema T, Topp A, Walter A, Wittwer MB, Wolfard J, Kuhn B, van der Stelt M, Martin RE, Grether U, Schneider G Nat Commun. 2025 Nov 26. doi: 10.1038/s41467-025-66324-4. PMID:41290653<ref>PMID:41290653</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | [[Category: | + | </div> |
| - | [[Category: | + | <div class="pdbe-citations 9i56" style="background-color:#fffaf0;"></div> |
| - | [[Category: | + | == References == |
| - | [[Category: | + | <references/> |
| - | [[Category: | + | __TOC__ |
| - | [[Category: | + | </StructureSection> |
| - | [[Category: Martin | + | [[Category: Homo sapiens]] |
| - | [[Category: | + | [[Category: Large Structures]] |
| - | [[Category: Stenzhorn | + | [[Category: Atz K]] |
| + | [[Category: Benz J]] | ||
| + | [[Category: Grether U]] | ||
| + | [[Category: Kuhn B]] | ||
| + | [[Category: Martin R]] | ||
| + | [[Category: Nippa D]] | ||
| + | [[Category: Stenzhorn Y]] | ||
| + | [[Category: Walter A]] | ||
Current revision
CRYSTAL STRUCTURE OF HUMAN MONOACYLGLYCEROL LIPASE WITH COMPOUND 23
| |||||||||||
Categories: Homo sapiens | Large Structures | Atz K | Benz J | Grether U | Kuhn B | Martin R | Nippa D | Stenzhorn Y | Walter A
